{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:50:03Z","timestamp":1785909003384,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmoop.2026.107769","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:55:35Z","timestamp":1780959335000},"page":"107769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"E.","family":"Salehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5430-8957","authenticated-orcid":false,"given":"E.L.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Augdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stalteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6791-2977","authenticated-orcid":false,"given":"K.E.","family":"Dibble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Faggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sammons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5203-4661","authenticated-orcid":false,"given":"S.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-167X","authenticated-orcid":false,"given":"N.","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"S.M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.esmoop.2026.107769_bib1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/ijd.13906","article-title":"Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review","volume":"57","author":"Rubio-Gonzalez","year":"2018","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107769_bib2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pon.3531","article-title":"Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients","volume":"23","author":"Choi","year":"2014","journal-title":"Psychooncology"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107769_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.7314\/APJCP.2012.13.4.1383","article-title":"Perception, attitudes, preparedness and experience of chemotherapy-induced alopecia among breast cancer patients: a qualitative study","volume":"13","author":"Kim","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107769_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological sequelae and alopecia among women with cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107769_bib5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"10390","key":"10.1016\/j.esmoop.2026.107769_bib6","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107769_bib7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107769_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2026.107769_bib9","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107769_bib10","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107769_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/annonc\/mdi088","article-title":"Prevention of chemotherapy-induced hair loss by scalp cooling","volume":"16","author":"Grevelman","year":"2005","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107769_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","article-title":"Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study","volume":"24","author":"Kang","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107769_bib13","doi-asserted-by":"crossref","first-page":"E442","DOI":"10.1002\/ijc.29115","article-title":"Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis","volume":"136","author":"Shin","year":"2015","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107769_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/0284186X.2012.658966","article-title":"Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients \u2013 results of the Dutch Scalp Cooling Registry","volume":"51","author":"van den Hurk","year":"2012","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107769_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41416-019-0520-8","article-title":"Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines","volume":"121","author":"Munzone","year":"2019","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107769_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.2016.20939","article-title":"Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial","volume":"317","author":"Nangia","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107769_bib17","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1093\/oncolo\/oyae116","article-title":"Results of the Dutch Scalp Cooling Registry in 7424 patients: analysis of determinants for scalp cooling efficacy","volume":"29","author":"Brook","year":"2024","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107769_bib18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107769_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdt476","article-title":"Development and validation of Chemotherapy-Induced Alopecia Distress Scale (CADS) for breast cancer patients","volume":"25","author":"Cho","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107769_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0959-8049(00)00353-1","article-title":"A body image scale for use with cancer patients","volume":"37","author":"Hopwood","year":"2001","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107769_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/00365518509155250","article-title":"Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man","volume":"45","author":"B\u00fclow","year":"1985","journal-title":"Scand J Clin Lab Invest"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107769_bib22","first-page":"2565","article-title":"Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment","volume":"21","author":"Betticher","year":"2013","journal-title":"Support Care Cancer"},{"issue":"20","key":"10.1016\/j.esmoop.2026.107769_bib23","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107769_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002800050807","article-title":"Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice","volume":"42","author":"Kumazawa","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107769_bib25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107769_bib26","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.3390\/ijms19113480","article-title":"Anthracyclines as topoisomerase II poisons: from early studies to new perspectives","volume":"19","author":"Marinello","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107769_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:29:39Z","timestamp":1785907779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926017114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2059702926017114"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107769","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107769"}}